NCT01130597
Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease
See it on ClinicalTrials.gov ↗63 people
38.1%
61.9%
24 womenmiddle line = equal numbers39 men
- Phase
- PHASE2
- Paid for by
- Relypsa, Inc.
- Finished
- 2010-09
- Health conditions
- Heart Failure
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 70.8 years
- Age 65+
- 73%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Females of child-bearing potential must be non-lactating, must have a negative serum pregnancy test at screening, and must have used a highly effective form of contraception for at least 3 months before study drug administration, during the…”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“…actating, must have a negative serum pregnancy test at screening, and must have used a highly effective form of contraception for at least 3 months before study drug administration, during the study, and for one month after study completion”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Uncorrected primary severe valvular disease, known obstructive or restrictive cardiomyopathy, uncontrolled or hemodynamically unstable arrhythmia”
- No cancer
Women with current or past cancer were turned away.
“Metastatic, late-stage or end-stage cancer with \< 12 months life expectancy or at risk for tumor lysis syndrome”
Study titles and rules are shown in their original English.